Participated · Seed · Feb 2026

Entirety Biomedical is a Michigan-based medical device startup creating absorbable metal implants that offer titanium-like strength during healing and then safely resorb once bone union is achieved. Its patented Curasorb alloy underpins plate-and-screw and headless compression screw systems aimed initially at lower-extremity and maxillofacial procedures, allowing surgeons to avoid permanent hardware without changing existing surgical workflows or reimbursement models. The company completed its first preclinical study in 2024 and is running three additional preclinical studies, with early data showing strong osseointegration. These studies will guide a planned first-in-human clinical trial of its lower-extremity headless compression screw system. Entirety works closely with surgeons and strategic partners to identify unmet fixation needs and translate them into products that improve patient outcomes and reduce secondary removal surgeries. Founded by materials-science engineers Jake Edick and Carolyn Woldring, the team brings more than a decade of absorbable magnesium R&D experience and multiple related patents. The startup recently secured $1.2 million in seed funding to advance product development toward clinical trials.

Led · Seed · Nov 2024

Biolux Technology develops light-accelerated orthodontic technologies; its flagship product, OrthoPulse, uses FDA-cleared, patented near-infrared light therapy to accelerate tooth movement. OrthoPulse is commercially available, reports an exceptionally low failure rate, and can cut treatment times by up to 50%, improving predictability of aligner treatments and patient compliance. The company plans to use new funding to launch a smart digital platform for OrthoPulse that offers real-time monitoring and treatment optimization for orthodontists and patients. Biolux will also accelerate product development, advance clinical research, and develop additional solutions to improve patient outcomes. Management changes include the appointment of Raphael Pascaud as Chairman and Marcel Pordes as CEO, supporting the company's next phase of growth. The announcement cites a broader orthodontic market valued at USD 9 billion in 2023 and projected to reach USD 21 billion by 2030 at a 15% CAGR. Biolux Research develops and commercializes light-accelerated orthodontic products, led by its FDA-cleared device OrthoPulse. OrthoPulse is a non-invasive therapy used ten minutes daily that the company says can accelerate orthodontic treatment by up to 50% and reduce patient pain for both aligner and fixed-appliance modalities. The device is currently sold in the United States, Europe, and Asia. Biolux highlights a strong portfolio of clinical data and emphasizes evidence-based innovation to enhance clinical outcomes and patient comfort. The company and its new leadership say they aim to make OrthoPulse part of the standard of orthodontic care globally. The recent financing and executive appointment are presented as validation and support for the company’s next growth phase.

Participated · Equity · Oct 2024

Toothio is a digital staffing marketplace that connects private dental practices and Dental Service Organizations (DSOs) with credentialed dental hygienists, assistants, and receptionists via a proprietary matching algorithm. It maintains a vetted pool of over 30,000 dental professionals and reports a 97% fill rate for open shifts. The platform added more than 15,000 professionals in 2024 and has driven 300% year-over-year growth since founding. Toothio’s product focuses on on-demand shift matching to streamline operations and maintain patient care quality while offering dental professionals flexible work. The company announced expansion into eight additional U.S. markets—Chicago, Los Angeles, San Jose, Portland, Seattle, Baltimore, Charlotte, and Orlando—to unlock access to thousands of practices and professionals. Founded in 2021, Toothio positions itself as a class-leading labor option for the dental industry. Toothio operates an on-demand staffing platform that gives dental practices quick access to hygienists and assistants to boost office production and patient support. Led by CEO Ian Prendergast, the company has facilitated thousands of completed shifts and expanded into Phoenix, Denver, Dallas, and Austin since founding in 2021. Toothio plans to enter three additional U.S. markets by the end of 2023 to increase access for practices, professionals, and DSOs. The company intends to use new capital to enhance its technology, grow its network of dental professionals, expand into key U.S. markets, and scale its sales team. To advance commercialization and scaling, Toothio appointed Keith Clements as Chief Commercial Officer to lead commercial expansion. The business model centers on alleviating staffing challenges for dentists through on-demand staffing solutions.

Led · Series A · Mar 2024

Odne develops a Root Preservation Therapy (RPT) technology platform that introduces three medical devices for minimally invasive root canal cleaning and light-cured obturation. Its platform includes the first hydro-dynamic cavitation device using saline for debridement and an FDA-cleared highly flowable, light-cured obturation material. Odne received FDA clearance for Odne™Cure and Odne™Fill in 2023 and plans product launches in 2024. To support US market entry the company has founded Odne Inc, USA, is running a Priority Access Program with US key opinion leaders, and will introduce the RPT workflow at the American Association of Endodontists meeting. The team is expanding to build training, service, marketing, and sales capabilities for the endodontic specialist market. Financially, Odne closed a $5.5M Series A1 round to fund its US market launch.

Participated · Equity · Mar 2024

Denturly is a Birmingham-based digital denture care firm that delivers digitally manufactured dentures and related services. The company plans to use new funding to drive UK expansion and scale operations across the country. Management expects to grow to more than 50 locations nationwide over the next 24 months and to triple headcount from 15 to 45 employees. The raise is positioned to support that rollout and broader efforts to “democratise quality digital denture care,” according to the CEO. The funding comes from a mix of public-region investment vehicles and private dental-focused investors, and will be managed in part by Midven. No revenue or user metrics were disclosed in the article.